New Biosimilars First Generic Drug Launches Oct. 25, 2024 - sulopenem etzadroxil and probenecid (Orlynvah) The FDA has approved Iterum’s Orlynvah for the treatment of uncomplicated urinary tract...

Cover image for Prime Therapeutics prioritizes patient-centered care, stays ahead of oncology trends Prime simplifies the cancer care pathway through innovative solutions that help manage complex...

Read Part 1 – Payer Survey Dive into Part 1 Hear from Prime’s medical pharmacy experts as they dive into the history of the report and offer their insights. Check out the events below to stay...

FDA approved BiTEs: Brand name Generic name Route Target Indication First FDA indication approval date Blincyto Blinatumomab IV anti-CD19 / anti-CD3 Acute lymphocytic leukemia 12/3/2014 Columvi...

Based on the clinical trial, there are certain expectations for how long patients can anticipate seeing the benefits of treatment. The median duration of response was 11.6 months (95% CI, 4.4 to...

This decision to remove REMS comes one year after the FDA loosened REMS requirements and removed the site mandate for CAR T educational and training materials because they deemed the product label...

Managed Markets Insight & Technology (MMIT)

Scientists have made remarkable progress in understanding the thousands of genes inside our cells and the link they may have to cancer. Researchers continue to discover patient-specific...